Recommended monthly dosing for selected self-injectable anti-TNF biologic medications for adult patients with moderately to severely active RA
SIMPONI® dosing offers the fewest injections of all SC anti-TNF options
SIMPONI® (golimumab): fewer injections1
|
SIMPONI® autoinjector + MTX1 |
Humira® (adalimumab) pen2 |
Enbrel® (etanercept) autoinjector3 |
|
|---|---|---|---|
| Minimum number of injections first year |
|
|
|
| Dosing schedule for adults with RA | 50 mg once a month |
40 mg every other week Some patients with RA not receiving MTX may benefit from increasing the frequency to 40 mg every week. |
50 mg once a week |
| Dosage form and strength | 50 mg per 0.5 mL of solution | 40 mg per 0.4 mL and 40 mg per 0.8 mL of solution | 50 mg per 0.98 mL of solution |
| Indications |
SIMPONI® is indicated for the treatment of adults with moderately to severely active RA, in combination with MTX.
|
Humira® is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Humira® can be used alone or in combination with MTX or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). | Enbrel® is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. Enbrel® can be initiated in combination with MTX or used alone. |
See below for additional dosing information.
Minimum number of injections first year
Dosing schedule for adults with RA
|
SIMPONI® autoinjector + MTX1 50 mg once a month |
|
Humira® (adalimumab) pen2 40 mg every other week Some patients with RA not receiving MTX may benefit from increasing the frequency to 40 mg every week. |
|
Enbrel® (etanercept) autoinjector4 50 mg once a week |
Dosage form and strength
|
SIMPONI® autoinjector + MTX1 50 mg per 0.5 mL of solution |
|
Humira® (adalimumab) pen2 40 mg per 0.4 mL and 40 mg per 0.8 mL of solution |
|
Enbrel® (etanercept) autoinjector4 50 mg per 0.98 mL of solution |
Indications
|
SIMPONI® autoinjector + MTX1 SIMPONI® is indicated for the treatment of adults with moderately to severely active RA, in combination with MTX. |
|
Humira® (adalimumab) pen2 Humira® is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Humira® can be used alone or in combination with MTX or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). |
|
Enbrel® (etanercept) autoinjector4 Enbrel® is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. Enbrel® can be initiated in combination with MTX or used alone. |
This presentation is not intended to compare the safety, efficacy, or indications of these treatments. While these factors are important, there are additional considerations for selecting a treatment. Please refer to each product’s Prescribing Information for additional information, including recommended dosing and administration.
SIMPONI® is intended for use under the guidance and supervision of a physician. Patients may self-inject with SIMPONI® after physician approval and proper training.
Prior to initiating SIMPONI® and periodically during therapy, patients should be evaluated for active tuberculosis and tested for latent infection. Prior to initiating SIMPONI®, patients should be tested for hepatitis B viral infection.
Prior TNF-alpha inhibitors used under the skin (subcutaneous injection) in a clinical study were Humira® and Enbrel®.
Humira is a registered trademark of AbbVie Inc. Enbrel is a registered trademark of Immunex Corporation.